Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details Textual)

v3.19.1
Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Jan. 01, 2019
Mar. 13, 2018
Mar. 12, 2018
Aug. 03, 2017
Apr. 07, 2017
Mar. 13, 2017
Mar. 13, 2016
Jan. 31, 2019
Jun. 30, 2018
Aug. 31, 2017
Apr. 24, 2017
Mar. 31, 2017
Feb. 28, 2017
Jan. 31, 2017
Oct. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jul. 31, 2018
Dec. 12, 2016
Jul. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued                               26,610,183 25,236,255        
Common Stock, Shares Authorized                               50,000,000 50,000,000        
Common Stock, Par or Stated Value Per Share                               $ 0.0001 $ 0.0001        
Common Stock, Voting Rights                               1.1          
Warrants Issued                       16,000   2,134,193              
Allocated Share-based Compensation Expense                               $ 34,000 $ 10,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                               5,500,000          
Common Stock, Shares Subscribed but Unissued                               709,314 834,756        
Common Stock, Value, Subscriptions                               $ 2,085,000 $ 9,558,000        
Shares Issued, Price Per Share     $ 11.45                                    
Payments of Stock Issuance Costs                               $ 0 $ 5,674,000        
Preferred Stock, Shares Authorized                               2,000,000 2,000,000        
Stock Issued During Period, Value, Issued for Services                         $ 1,700,000                
Proceeds from Issuance of Private Placement                             $ 10,000,000            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights                               The remaining 50% (the “Performance Options”) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $1,000,000,000.          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value                               $ 5.73          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate                               0.00%          
Research and Development Expense                               $ 2,100,000          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                               2,049,689          
Maximum Value Of Shares Authorized                                     $ 75,000,000    
Commission Rate Percentage                                     3.00%    
Preferred Stock, Dividend Rate, Percentage               2.00%                          
Maximum [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized                 5,000,000                        
Minimum [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized                 3,000,000                        
Incentive Plan 2016 [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period                               10 years          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized                               2,000,000          
Restricted Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Allocated Share-based Compensation Expense                               $ 1,900,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                               322,636 180,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                               2 years 6 months          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value                               $ 5.78 $ 5.73        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number                               68,158          
Restricted Stock Units (RSUs) [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Allocated Share-based Compensation Expense                               $ 4,200,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                               1,072,000 134,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                               2 years 2 months 12 days          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value                               $ 8.16 $ 6.53        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number                               230,000          
Employee Stock Option [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock Repurchased During Period, Shares                     1,041,675                    
Allocated Share-based Compensation Expense                               $ 1,100,000          
Shares Issued, Price Per Share         $ 5.73           $ 5.73                    
Stock Issued During Period, Shares, Issued for Services         200,000                                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term                               2 years          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeiture Rate                                 0.00%        
Employee Stock Option [Member] | Restricted Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value                               $ 5.73          
General and Administrative Expense [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Allocated Share-based Compensation Expense                               $ 1,200,000          
Common Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Preferred Stock, Shares Authorized                               5,000,000 2,000,000        
Unregistered Common Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock Issued During Period, Shares, New Issues                       64,000   8,536,774              
Common Class B [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares Authorized                                         15,000,000
Common Class A [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued                               1,000,000 1,000,000        
Common Stock, Shares Authorized                                   1,000,000      
Fortress Biotech, Inc [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued     834,756             365,639                      
Common Stock, Value, Subscriptions                                       $ 900,000  
Shares Issued, Price Per Share           $ 5.73                              
Stock Issued During Period, Shares, Issued for Services 709,314         767,264                              
Stock Issued During Period, Value, Issued for Services           $ 4,400,000                              
Research and Development Expense                                 $ 9,600,000        
Common Stock, Capital Shares Reserved for Future Issuance   834,756 834,756                                    
Preferred Stock, Dividend Rate, Percentage 2.00% 2.50% 2.50%             2.50%                      
Fortress Biotech, Inc [Member] | Common Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Shares Of Common Stock, Percentage                               2.50%          
Stock Issued During Period, Shares, New Issues                               982,533          
Common Stock, Shares Subscribed but Unissued                                   2,000,000      
Research and Development Expense                                 $ 9,600,000        
Fortress Biotech, Inc [Member] | Common Class B [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued             250,000                            
Common Stock, Shares Subscribed but Unissued                                   7,000,000      
Diluted Outstanding Equity, Percentage             2.50%                            
Fortress Biotech, Inc [Member] | Common Stock B Two [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued           767,264                              
Research and Development Expense                                   $ 4,400,000      
Preferred Stock, Dividend Rate, Percentage           2.50%                              
National Holdings Corporation [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Warrants Issued       2,500                                  
National Holdings Corporation [Member] | Unregistered Common Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock Issued During Period, Shares, New Issues       10,000                                  
City of Hope National Medical Center [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock Issued During Period, Shares, New Issues                         293,588                
City of Hope National Medical Center [Member] | Common Stock [Member] | Original Agreement [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Shares, Issued                               293,588          
City of Hope National Medical Center [Member] | Common Class A [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Shares, Issued                               1,000,000          
National Securities, Inc [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Percentage Of Shares Issued To Placement Agent       10.00%                                  
Warrants Issued       1,000               6,400   853,677              
Private Placement [Member] | National Holdings Corporation [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Percentage Of Placement Agent Fee                       10.00%   10.00%              
Percentage Of Shares Issued To Placement Agent                       10.00%   10.00%              
Payments of Stock Issuance Costs                       $ 42,000   $ 5,500,000              
Proceeds from Issuance of Private Placement       $ 65,000               $ 400,000   $ 55,500,000